Heart Center, Turku University Hospital and University of Turku, Hämeenkatu 11, 20521, Turku, Finland.
MediCity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Tykistönkatu 6A, 20520, Turku, Finland.
Sci Rep. 2021 Nov 15;11(1):22230. doi: 10.1038/s41598-021-01695-4.
Patients undergoing cardiac surgery develop a marked postoperative systemic inflammatory response. Blood transfusion may contribute to disruption of homeostasis in these patients. We sought to evaluate the impact of blood transfusion on serum interleukin-6 (IL-6), hypoxia induced factor-1 alpha (HIF-1α) levels as well as adverse outcomes in patients undergoing adult cardiac surgery. We prospectively enrolled 282 patients undergoing adult cardiac surgery. Serum IL-6 and HIF-1α levels were measured preoperatively and on the first postoperative day. Packed red blood cells were transfused in 26.3% of patients (mean 2.93 ± 3.05 units) by the time of postoperative sampling. Postoperative IL-6 levels increased over 30-fold and were similar in both groups (p = 0.115), whilst HIF-1α levels (0.377 pg/mL vs. 0.784 pg/mL, p = 0.002) decreased significantly in patients who received red blood cell transfusion. Moreover, greater decrease in HIF-1α levels predicted worse in-hospital and 3mo adverse outcome. Red blood cell transfusion was associated with higher risk of major adverse outcomes (stroke, pneumonia, all-cause mortality) during the index hospitalization. Red blood cell transfusion induces blunting of postoperative HIF-1 α response and is associated with higher risk of adverse thrombotic and pulmonary adverse events after cardiac surgery. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT03444259.
患者在接受心脏手术后会出现明显的术后全身炎症反应。输血可能会导致这些患者的体内平衡紊乱。我们试图评估输血对接受成人心脏手术患者的血清白细胞介素-6(IL-6)、缺氧诱导因子-1 阿尔法(HIF-1α)水平以及不良预后的影响。我们前瞻性地纳入了 282 名接受成人心脏手术的患者。在术前和术后第 1 天测量了血清 IL-6 和 HIF-1α 水平。在术后采样时,26.3%的患者(平均 2.93±3.05 单位)输注了浓缩红细胞。术后 IL-6 水平增加了 30 多倍,两组间无差异(p=0.115),而接受输血的患者 HIF-1α 水平(0.377pg/mL 与 0.784pg/mL,p=0.002)显著下降。此外,HIF-1α 水平下降越大,住院期间和 3 个月的不良预后越差。输血与指数住院期间主要不良结局(中风、肺炎、全因死亡率)的风险增加相关。输血可诱导术后 HIF-1α 反应减弱,与心脏手术后血栓和肺部不良事件的风险增加相关。临床试验注册 ClinicalTrials.gov 标识符:NCT03444259。